Table 3Characteristics of populations studied

Authora, YearReference StandardAge Distribution in Years Mean (sd) / Median (Range)Race Distribution, %% Positive DRE% Positive Family HistoryCoexisting Pathology Name, %
Adam90, 2011BiopsyNR / 67 (35-89)White 25.7; AA 68.6; Other 5.748.64.8NR
Ankerst65, 2008BiopsyNR / 66 (11-83)White 97.5; AA 2.0; Other 0.518.7NRNR
Aubin91, 2010Biopsy66.1 (6.0) / 66.1 (52.7-80)NRNR13.8NR
Auprich92,2011BiopsyNR / 63 (50-70)NR11NRNR
Auprich112,2011PNR / 63 (44-79)NR23.9NRNR
Bollito93, 2012BiopsyNR / 67 (42-89)NR0NRNR
Cao94, 2011BiopsyNRAsian (Chinese) 100NRNRNR
de la Taille95, 2011Biopsy63 (7.6) / 63NRNRNRNR
Deras96, 2008Biopsy64 / 64 (32-89)White 82.5; AA 5.3; Hispanic 2.3; Asian 0.4; Other 9.6NRNRNR
FDA Summary97, 2012BiopsyNR / 67 (44-92)White 87.5; AA 9.1; Other 2.6NRNRNR
Feero98, 2012BiopsyNR / 64 (48-87)NR0NRHGPIN, 24; BPH, 44
Goode99, 2012BiopsyNR / 66 (41-90)NRNRNRHGPIN; ASAP
Hessels100, 2010Biopsy63 / 64 (38-83)NRNRNRNR
Kusuda88, 2011P67.2 (6.5) / NRNRNRNRNR
Liss114, 2011P62.7 (7.2) / NRNR16NRNR
Mearini101, 2009BiopsyNRNRNRNRBPH, 27
Nakanishi115, 2008P60 / 60 (45-70)White 78.1; AA 15.6; Hispanic 6.3NRNRNR
Nyberg102, 2010BiopsyNR / 63 (IQR 57-70)NRNRNRHGPIN, 5
Ochiai103, 2011BiopsyNR / 66 (44-87)Asian (Japanese) 100NRNRNR
Ouyang104, 2009BiopsyNRWhite 98; AA 2NRNRNR
Pepe105, 2012BiopsyNR / 64 (48-74)NRNRNRNR
Perdona31, 2011BiopsyNR / 66 (60-72)NRNR4.6NR
Ploussard106, 2010Biopsy64.6 / 65.4 (43.3-83.4)NRNRNRASAP, 4
Ploussard116, 2011P62 / 62 (43-75)NRNRNRNR
Rigau107, 2010BiopsyMean 65.7 / Range 44-85NR26.5NRNR
Roobol108, 2010Biopsy70.0 / 70.2 (63.6-77.5)NR13.1NRNR
Schilling109, 2010BiopsyNR / 67 (42-88)NRNRNRNR
Tosoian89, 2010Biopsy surveillance68.2 (6.2) / 68.2 (50.3-84.2)White 91.8; AA 5.4; Other 2.8NRNRNR
Vlaeminck-Guillem118, 2011P62 (6) / 63 (47-72)NRNRNRNR
Wang110,2009Biopsy62 (8.3) / Median NR (44-86)White 91.5; AA 5.3; Other 3.21618.7HGPIN, 5.9
ASAP, 2.1
Whitman119, 2008PNR / 58 (42-73)White 75; AA 25NRNRNR
Wu111, 2012Biopsy63.5 (7.4) / NRNR13NRHGPIN; ASAP

AA = African American; ASAP = atypical small acinar proliferation; BPH = benign prostatic hyperplasia; DRE = digital rectal exam; HGPIN = high-grade prostatic intraepithelial neoplasia; sd = standard deviation; tPSA = total prostate specific antigenNR = not reported; P = prostatectomy

a

Shaded rows indicate studies focusing on the “grey zone” of tPSA (e.g., 2.5-10 ng/mL) when enrolling patients. Rows 3, 8, 11, and 21-23 are shaded.

From: Results

Cover of PCA3 Testing for the Diagnosis and Management of Prostate Cancer
PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet].
Comparative Effectiveness Reviews, No. 98.
Bradley LA, Palomaki G, Gutman S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.